Mitsubishi UFJ Asset Management Co. Ltd. Has $533.96 Million Stock Position in Zoetis Inc. $ZTS

Mitsubishi UFJ Asset Management Co. Ltd. lessened its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,240,452 shares of the company's stock after selling 72,327 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.96% of Zoetis worth $533,958,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock worth $6,011,802,000 after buying an additional 5,474,210 shares during the period. Nordea Investment Management AB raised its position in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the period. Alliancebernstein L.P. grew its position in Zoetis by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company's stock valued at $620,595,000 after purchasing an additional 496,320 shares during the period. Fundsmith LLP increased its stake in Zoetis by 25.3% during the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company's stock valued at $528,966,000 after purchasing an additional 730,300 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Zoetis by 4.6% during the third quarter. Invesco Ltd. now owns 3,371,032 shares of the company's stock worth $493,249,000 after buying an additional 147,271 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Price Performance

ZTS stock opened at $112.60 on Wednesday. The firm has a market cap of $47.36 billion, a P/E ratio of 18.70, a P/E/G ratio of 1.73 and a beta of 0.87. Zoetis Inc. has a 52 week low of $111.27 and a 52 week high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The firm's fifty day moving average is $119.61 and its 200 day moving average is $124.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the previous year, the firm earned $1.40 earnings per share. The firm's revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts predict that Zoetis Inc. will post 7.01 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. Zoetis's dividend payout ratio is 35.22%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. BTIG Research reissued a "buy" rating and set a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. UBS Group cut their price target on Zoetis from $136.00 to $130.00 and set a "neutral" rating for the company in a research note on Tuesday, April 28th. William Blair reissued an "outperform" rating on shares of Zoetis in a research note on Monday, March 2nd. Leerink Partners restated a "market perform" rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, Bank of America upped their price target on Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a report on Friday, February 13th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $151.75.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.